BMS Kicks Off 2021 with $70 Million Collab for Next-Gen T Cell Cancer Therapies

Privately-held San Francisco, Cailf.-based programmable cell therapy company ArsenalBio has entered into a multi-year discovery partnership with Bristol Myers Squibb to develop next-generation T cell therapies for solid tumors.